Cargando…
Definitive Cefazolin Therapy for Stabilized Adults with Community-Onset Escherichia coli, Klebsiella Species, and Proteus mirabilis Bacteremia: MIC Matters
Background: Cefazolin is in vitro active against wild isolates of Escherichia coli, Klebsiella species, and Proteus mirabilis (EKP), but clinical evidence supporting the contemporary susceptibility breakpoint issued by the Clinical and Laboratory Standards Institute (CLSI) are limited. Methods: Betw...
Autores principales: | Hsieh, Chih-Chia, Chen, Po-Lin, Lee, Chung-Hsun, Yang, Chao-Yung, Lee, Ching-Chi, Ko, Wen-Chien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019784/ https://www.ncbi.nlm.nih.gov/pubmed/31936020 http://dx.doi.org/10.3390/jcm9010157 |
Ejemplares similares
-
Definitive Cefazolin Treatment for Community-Onset Enterobacteriaceae Bacteremia Based on the Contemporary CLSI Breakpoint: Clinical Experience of a Medical Center in Southern Taiwan
por: Lee, Ching-Chi, et al.
Publicado: (2019) -
Propensity score matched analysis comparing the clinical outcome of Klebsiella pneumoniae and Escherichia coli causing community-onset monomicrobial bacteremia
por: Kuo, Tsung-Hang, et al.
Publicado: (2017) -
Risk Factors for Bloodstream Infections Due to ESBL-Producing Escherichia coli, Klebsiella spp., and Proteus mirabilis
por: Vance, Mary Kathryn, et al.
Publicado: (2023) -
Proteus mirabilis thoracic vertebral osteomyelitis: a case report
por: Chiang, Ming-Hsiu, et al.
Publicado: (2021) -
A Simple Scoring Algorithm That Predicts Abscesses in Adults with Community-Onset Klebsiella pneumoniae Bacteremia: Hypermucoviscosity Matters
por: Hong, Ming-Yuan, et al.
Publicado: (2020)